MedTrace Logo

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

NCT05065619 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.

Conditions

Interventions

BIOLOGICAL

MT-2766 High dose (3.75 µg)

Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

DRUG

Placebo

Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

BIOLOGICAL

MT-2766 Low dose

Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    collaborator INDUSTRY

  • Medicago

    lead INDUSTRY

Principal Investigators

  • Medical Director · Medicago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-02
Primary Completion
2022-03-12
Completion
2023-01-29
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065619 on ClinicalTrials.gov